10x Genomics settles all patent litigation with Bio-Rad, enters global cross-license for single cell analysis

10x Genomics, Inc.

Cross license covers single cell analysis; excludes spatial, in situ, and digital PCR (for 10x).
10x to pay Bio-Rad $29.4M in royalties/interest for past GEM sales; $15.4M reversal in Q2 2021.
Future royalty payments expected to impact gross margins by less than 1% through 2030.
All outstanding litigation dismissed with prejudice.
Agreement term is life of licensed patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.